Embla Competitors

EMBLA Stock

34.90 0.70 1.97%

Embla Medical hf competes with Danske Andelskassers, Ringkjoebing Landbobank, Moens Bank, Laan Spar, and Nordinvestments; as well as few others. Analyzing Embla Medical competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Embla Medical to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

You can use the Comparative Equity Analysis module to analyze the advantages of investing in your portfolio's related equities across multiple sectors and thematic ideas. Please use the input box below to enter symbols for particular investments you would like to analyze. With the equity comparison module, you can estimate the relative effect of Embla Medical competition on your existing holdings.

Specify up to 10 symbols:

Please note, it is not enough to conduct a financial or market analysis of a single entity such as Embla Medical. Your research has to be compared to or analyzed against Embla Medical's peers to derive any actionable benefits. When done correctly, Embla Medical's competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy toward taking a position in Embla Medical hf.

Embla Medical Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Embla Medical and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Embla and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Embla Medical hf does not affect the price movement of the other competitor.

	DAB	RILBA	MNBA	LASP	NORD	KRE	NTG
DAB		0.53	-0.59	-0.05	0.0	0.35	0.4	DAB
RILBA	0.53		-0.81	0.26	0.0	0.1	0.12	RILBA
MNBA	-0.59	-0.81		-0.26	0.0	-0.11	-0.22	MNBA
LASP	-0.05	0.26	-0.26		0.0	-0.11	-0.07	LASP
NORD	0.0	0.0	0.0	0.0		0.0	0.0	NORD
KRE	0.35	0.1	-0.11	-0.11	0.0		0.22	KRE
NTG	0.4	0.12	-0.22	-0.07	0.0	0.22		NTG
	DAB	RILBA	MNBA	LASP	NORD	KRE	NTG

Click cells to compare fundamentals

Check Volatility

Backtest Portfolio

High positive correlations

RILBA	+ 0.53	DAB
NTG	+ 0.4	DAB
KRE	+ 0.35	DAB
LASP	+ 0.26	RILBA
NTG	+ 0.22	KRE
NTG	+ 0.12	RILBA

High negative correlations

MNBA	- 0.81	RILBA
MNBA	- 0.59	DAB
LASP	- 0.26	MNBA
NTG	- 0.22	MNBA
KRE	- 0.11	LASP
KRE	- 0.11	MNBA

Risk-Adjusted Indicators

There is a big difference between Embla Stock performing well and Embla Medical Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Embla Medical's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.

	Mean Deviation	Jensen Alpha	Sortino Ratio	Treynor Ratio	Semi Deviation	Expected Shortfall	Potential Upside	Value @Risk	Maximum Drawdown
DAB	0.90	0.09	(0.05)	(0.55)	0.87	(1.32)	1.97	(1.56)	7.32
RILBA	0.87	0.07	(0.07)	(0.46)	1.00	(0.89)	1.65	(1.58)	6.24
MNBA	0.76	(0.07)	0.00	0.56	0.00	0.00	1.79	(1.77)	6.21
LASP	0.88	0.02	(0.04)	0.19	0.99	(1.89)	2.27	(1.49)	8.36
NORD	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
KRE	0.79	0.02	(0.09)	(0.01)	0.97	(1.14)	1.41	(1.96)	4.35
NTG	1.55	0.07	(0.03)	1.46	1.91	(1.63)	4.46	(2.63)	13.56

Unable to evaluate fundamental data of Embla Medical hf at this time. Please try again later

All Fundamental Data

Embla Medical Competitive Analysis

The better you understand Embla Medical competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Embla Medical's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Embla Medical's competition over several years is one of the best ways to analyze its investment potential.

Better Than Average

Worse Than Peers

View Performance Chart

	EMBLA	DAB	RILBA	MNBA	LASP	NORD	KRE	NTG
	1.97 34.90 Embla	0.79 12.60 Danske	0.61 1,150 Ringkjoebing	0.92 216.00 Moens	2.26 680.00 Laan	0.00 1.23 Nordinvestments	0.99 5,000 Kreditbanken	0.70 285.00 NTG
Market Volatility (90 Days Market Risk)	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady	Very steady
Market Performance (90 Days Performance)	Good	Insignificant	Modest	Very Weak	Very Weak	Very Weak	Very Weak	Insignificant
Odds of Financial Distress (Probability Of Bankruptcy)	Unknown	About Average	Below Average	Below Average	Low	Quite High	Low	Low
Current Valuation (Equity Enterprise Value)	Under Valued	Fairly Valued	Over Valued	Over Valued	Over Valued	Fairly Valued	Over Valued	Over Valued
Buy or Sell Advice (Average Analysts Consensus)	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available	Not Available
Trade Advice (90 Days Macroaxis Advice)	Strong Hold	Cautious Hold	Strong Sell	Strong Sell	Hold	Hold	Sell	Strong Sell
Current Ratio		N/A	N/A	N/A	N/A	N/A	N/A	0.92 X
Net Asset		13.5 B	68.98 B	4.02 B	30.02 B	51.45 M	5.1 B	3.24 B
Profit Margin		0.19 %	0.54 %	0.21 %	0.20 %	(2.01) %	0.27 %	0.05 %
EBITDA		229.68 M	1.67 B	49.9 M	360.25 M	(15.52 M)	104.72 M	670 M
Operating Margin		0.19 %	0.67 %	0.26 %	0.24 %	(2.11) %	0.34 %	0.07 %
Current Valuation		362.48 M	27.37 B	(969.98 M)	(8.08 B)	18.31 M	34.1 M	5.82 B
Price To Book		0.84 X	2.75 X	0.73 X	0.96 X	1.35 X	0.85 X	5.42 X
Retained Earnings		269 M	3.27 B	254 M	783 M	N/A	417 M	N/A
Current Asset		977 M	4.69 B	157 M	2.02 B	N/A	273 M	N/A
Five Year Return		N/A	1.89 %	4.75 %	1.93 %	N/A	1.14 %	N/A
Beta		0.4	0.68	0.47	0.0631	N/A	0.35	1.62
Number Of Employees		303	646	96	22	16	84	1.88 K
Shares Outstanding		185.88 M	27.48 M	2 M	3.46 M	20.62 M	168.2 K	21.77 M
Cash Flow From Operations		589.95 M	(671.69 M)	746.43 M	2.49 B	(62.47 M)	(259.65 M)	461.6 M
Annual Yield		0.03 %	0.01 %	N/A	0.01 %	N/A	0.01 %	N/A
Total Debt		783.1 M	9.15 B	85.04 M	174.74 M	N/A	88.31 M	626.7 M
Return On Equity		0.0517	0.17	0.0731	0.0871	-0.22	0.0612	0.63
Z Score		1.2	1.8	2.4	7.8	N/A	4.8	8.0
Return On Asset		0.0081	0.0231	0.0097	0.007	-0.14	0.0094	0.11
Book Value Per Share		9.86 X	337.40 X	279.72 X	701.03 X	2.17 X	4,795 X	44.76 X
Current Liabilities		9.24 B	17.54 B	1.78 B	14.01 B	N/A	2.06 B	N/A
Total Asset		13.5 B	68.98 B	4.02 B	30.02 B	51.45 M	5.1 B	3.24 B
Last Dividend Paid		0.29	7.0	2.0	N/A	N/A	50.0	N/A
Target Price		N/A	1000.0	N/A	N/A	N/A	N/A	340.0
Debt To Equity		N/A	N/A	N/A	N/A	N/A	N/A	1.43 %
Shares Owned By Institutions		0.21 %	34.66 %	0.27 %	11.44 %	31.30 %	0.20 %	21.26 %
Market Capitalization		1.92 B	29.14 B	418 M	2.28 B	64.49 M	719.9 M	6.73 B
Price To Earning		7.95 X	28.01 X	7.26 X	9.24 X	N/A	8.68 X	74.71 X
Price To Earnings To Growth		N/A	1.76 X	N/A	N/A	N/A	N/A	N/A
Price To Sales		3.14 X	9.36 X	2.17 X	2.29 X	15.30 X	3.82 X	0.53 X
Net Income		202.02 M	1.49 B	57.21 M	203.03 M	(15.3 M)	92.5 M	349 M
Earnings Per Share		0.60 X	53.40 X	20.01 X	49.50 X	(0.82) X	286.40 X	22.03 X
Shares Owned By Insiders		82.68 %	0.55 %	26.53 %	34.90 %	37.16 %	38.00 %	32.49 %
Revenue		662.48 M	2.8 B	174.51 M	1.08 B	4.46 M	210.23 M	7.3 B
Working Capital		(8.26 B)	(12.85 B)	(1.62 B)	(11.99 B)	N/A	(1.79 B)	N/A
Cash And Equivalents		1.38 B	5.83 B	65.36 M	5.51 B	N/A	66.49 M	177.8 M
Cash Per Share		10.54 X	211.43 X	32.86 X	N/A	N/A	395.14 X	7.96 X
Gross Profit		677.02 M	2.79 B	187.78 M	1.02 B	(6.99 M)	227.61 M	1.59 B
Day Typical Price	35.27	12.58	1152.0	217.33	680.0	1.23	5016.67	285.0
Accumulation Distribution	0.0306	0.004	0.0155	0.0182	N/A	N/A	0.0099	0.0174
Market Facilitation Index	1.1	0.05	18.0	4.0	N/A	N/A	50.0	5.0
Daily Balance Of Power	(0.64)	(2.00)	(0.39)	(0.50)	9.2 T	0.0	(1.00)	(0.40)
Period Momentum Indicator	(0.70)	(0.10)	(7.00)	(2.00)	15.0	N/A	(50.00)	(2.00)
Rate Of Daily Change	0.98	0.99	0.99	0.99	1.02	1.0	0.99	0.99
Day Median Price	35.45	12.58	1153.0	218.0	680.0	1.23	5025.0	285.0
Price Action Indicator	(0.90)	(0.03)	(6.50)	(3.00)	7.5	N/A	(50.00)	(1.00)
Coefficient Of Variation	523.21	1537.07	1735.02	(1,422)	2190.01	N/A	9126.85	2643.78
Mean Deviation	1.15	0.8972	0.8699	0.7611	0.8841	N/A	0.7859	1.55
Jensen Alpha	0.2711	0.0883	0.0707	(0.07)	0.0192	N/A	0.021	0.0669
Total Risk Alpha	0.0235	(0.14)	(0.13)	(0.27)	(0.19)	N/A	(0.18)	(0.29)
Sortino Ratio	0.1027	(0.05)	(0.07)	N/A	(0.04)	N/A	(0.09)	(0.03)
Downside Variance	1.52	1.32	1.13	N/A	3.01	N/A	2.12	4.11
Standard Deviation	1.38	1.25	1.14	1.08	1.48	N/A	1.07	2.2
Kurtosis	(0.49)	2.76	2.21	1.23	4.9	N/A	(0.20)	2.4
Potential Upside	2.58	1.97	1.65	1.79	2.27	N/A	1.41	4.46
Treynor Ratio	(1.94)	(0.55)	(0.46)	0.5627	0.1917	N/A	(0.01)	1.46
Maximum Drawdown	6.03	7.32	6.24	6.21	8.36	N/A	4.35	13.56
Variance	1.91	1.57	1.29	1.17	2.18	N/A	1.15	4.84
Market Risk Adjusted Performance	(1.93)	(0.54)	(0.45)	0.5727	0.2017	N/A	(0)	1.47
Risk Adjusted Performance	0.1506	0.0536	0.0473	(0.05)	0.0397	N/A	0.0112	0.0354
Skewness	0.1394	1.03	0.875	(0.37)	0.9968	N/A	(0.35)	0.8057
Semi Deviation	0.933	0.8691	0.9956	N/A	0.9876	N/A	0.974	1.91
Information Ratio	0.0917	(0.04)	(0.06)	(0.20)	(0.05)	N/A	(0.12)	(0.02)
Value At Risk	(1.91)	(1.56)	(1.58)	(1.77)	(1.49)	N/A	(1.96)	(2.63)
Expected Short fall	(1.58)	(1.32)	(0.89)	N/A	(1.89)	N/A	(1.14)	(1.63)
Downside Deviation	1.23	1.15	1.07	N/A	1.73	N/A	1.46	2.03
Semi Variance	0.8705	0.7553	0.9912	N/A	0.9754	N/A	0.9486	3.64

Embla Medical Competition Performance Charts

Five steps to successful analysis of Embla Medical Competition

Embla Medical's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Embla Medical hf in relation to its competition. Embla Medical's competition analysis typically involves several steps, including:

Identifying the key players in the market: This involves identifying the major competitors of Embla Medical in the market, both direct and indirect, as well as new entrants and disruptive technologies.
Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Embla Medical's competitive landscape.
Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Embla Medical hf, and developing a strategy to address them.
Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.

Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Embla Medical position

In addition to having Embla Medical in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Consumer Discretionary ETFs Thematic Idea Now

Consumer Discretionary ETFs

ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Consumer Discretionary ETFs theme has 29 constituents at this time.

You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Consumer Discretionary ETFs Theme or any other thematic opportunities.

View All Next

Launch

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC